Caterina Messina

2469P Bone marrow adipose tissue (BMAT) assessment in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to androgen deprivation therapy + enzalutamide +/- zoledronic acid - The BonEnza study

Marco Bergamini, Alberto Dalla Volta, Francesca Valcamonico, Martina Buffoni et autres

it (code pays fourni par la source)

Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial

Alberto Dalla Volta, Francesca Valcamonico, Andrea Zivi, Giuseppe Procopio et autres

it, ca, us (code pays fourni par la source)

Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study

Martina Buffoni, Alberto Dalla Volta, Francesca Valcamonico, Marco Bergamini et autres

BACKGROUND AND OBJECTIVE: The reduction of lean body mass (LBM) and the increase of fat body mass (FBM) caused by androgen deprivation therapy (ADT) administered to prostate cancer patients are well known to lead to an increased risk of sarcopenia. The effects …

it (code pays fourni par la source)

P254 REAl-world Data from an Italian Compassionate Use Program (CUP) of avelumab first- Line Maintenance (1LM) for locallY advanced or metastatic Urothelial Carcinoma (la/mUC): Outcomes from the READY study in patients (pts) with low tumor burden

Lorenzo Antonuzzo, Marco Maruzzo, U. De Giorgi, D. Santini et autres

READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma

Lorenzo Antonuzzo, Marco Maruzzo, U. De Giorgi, D. Santini et autres

Background Avelumab first-line (1L) maintenance is recommended as the standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without disease progression following 1L platinum-based chemotherapy (PBC). We report results from READY, a real-world study of avelumab 1L maintenance …

it, ch (code pays fourni par la source)

1624P Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study

Martina Buffoni, Alberto Dalla Volta, Francesca Valcamonico, Duncan Apollo et autres

it (code pays fourni par la source)

Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide

Alberto Dalla Volta, Francesca Valcamonico, Andrea Zivi, Giuseppe Procopio et autres

it (code pays fourni par la source)

1785P Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study

Alberto Dalla Volta, Francesca Valcamonico, Andrea Zivi, Giuseppe Procopio et autres

it (code pays fourni par la source)

P-26 Is there room for nal-IRI in biliary tract cancer?

Valeria Merz, Caterina Messina, Camilla Zecchetto, Alberto Quinzii et autres

it, us (code pays fourni par la source)

Whole-body diffusion-weighted magnetic resonance imaging to assess bone response in patients with hormone-sensitive metastatic prostate cancer randomly assigned to receive androgen deprivation + enzalutamide ± zoledronic acid.

Alberto Dalla Volta, Francesca Valcamonico, Andrea Zivi, Giuseppe Procopio et autres

46 Background: Bone is frequently involved in metastatic hormone sensitive prostate cancer (mHSPC). Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) is a promising imaging technique for the assessment of bone response in prostate cancer. It is not known whether the addition of antiresorptive …

it (code pays fourni par la source)

Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

Orazio Caffo, Cinzia Ortega, Franco Nolè, Donatello Gasparro et autres

it (code pays fourni par la source)

Supplementary Material for: Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Francesco Tovoli, Vincenzo Dadduzio, Stephanie DeLorenzo, Lorenza Rimassa et autres

Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontline setting. Real-life clinical data of cabozantinib for HCC are …